Information Provided By:
Fly News Breaks for February 10, 2016
CTIC
Feb 10, 2016 | 05:58 EDT
Piper Jaffray analyst Charles Duncan downgraded CTI BioPharma to Neutral after the FDA placed pacritinib on a full clinical hold. The news introduces "greater risk and longer timelines and financial investment" for the program, Duncan tells investors in a research note. He cut his price target for CTI shares to 75c from $4.
News For CTIC From the Last 2 Days
There are no results for your query CTIC